ClinicalTrials.gg
CompletedNCT01382719Updated Dec 18, 2014Results posted

Bremelanotide in Premenopausal Women With Female Sexual Arousal Disorder and/or Hypoactive Sexual Desire Disorder

A Phase 2 interventional study of bremelanotide in Female Sexual Arousal Disorder and Hypoactive Sexual Desire Disorder, sponsored by Palatin Technologies, Inc. Completed at 68 sites in 2 countries. Open to female participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2014-12-18.

Sponsored by Palatin Technologies, Inc · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
612
Allocation
Randomized
Ages
21 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 62 studies in Sexual Dysfunctions, Psychological with a site in United States — 3 open to participants now, 6 under way, none of them phase 3. Sexual Dysfunctions, Psychological · United States.

Enrollment
15th of 59
612 · median 196
Started
2011
with 2 others
Phase 2
13 of 62
1 open now
Registered
30th of 62
by date
Lead sponsor
4 of 62
Palatin Technologies, Inc

Among the 62 studies in Sexual Dysfunctions, Psychological with a site in United States, this one is the 15th largest by enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2011, is one of 13 in phase 2, and was the 30th registered.

Sexual Dysfunctions, Psychological

138 studies on the registry are indexed under Sexual Dysfunctions, Psychological; 10 are open to participants now.

Browse Sexual Dysfunctions, Psychological studies →

Open to participants now

3 of the 62 studies in Sexual Dysfunctions, Psychological with a site in United States are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Sexual Dysfunctions, Psychological studies recruiting now, 2 set no upper age limit and 1 stops at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 21 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Sexual Dysfunctions, Psychological with a site in United States, or all of them as a file.
02

Study summary

This trial is designed to evaluate the efficacy and safety of 3 fixed dose levels of bremelanotide, administered subcutaneously on an as-needed basis under conditions of home use, for the treatment of female sexual arousal disorder (FSAD), hypoactive sexual desire disorder (HSDD), or mixed FSAD/HSDD in premenopausal women.

03

Conditions studied

  • Female Sexual Arousal Disorder
  • Hypoactive Sexual Desire Disorder

Keywords

  • FSAD
  • HSDD
  • female sexual dysfunction
  • FSD
  • Female Sexual Arousal Disorder
  • Hypoactive Sexual Desire Disorder
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Female, at least 21 years of age, and premenopausal Previously experienced sexual arousal during sexual activity and/or normal level of desire in the past for least 2 years.

Willing to engage in sexual activities Currently in stable relationship with a partner(male or female)for at least 6 months.

If subject has a male sexual partner, has recorded a score of "not impotent" or "minimally impotent" on Single-question Assessment of ED.

For at least 6 months before Screening, has met diagnostic criteria for FSAD, HSDD, or mixed FSAD/HSDD Has a negative serum pregnancy test (hCG) at Screening and, if subject's partner is male, has used a medically acceptable form of for the 3 months before Screening (Visit 1), and is willing to continue for the duration of the trial and 1 month following the last dose of trial drug.

Has a normal pelvic examination. At Screening or documented within 12 months before Screening, has:normal Pap test results with or without history of positive HPV, dysplasia, or ASCUS that has resolved or been treated;Pap test results positive for ASCUS and negative for HPV;Pap test results positive for HPV AND no ASCUS or dysplasia on Pap or condyloma present upon examination.

At Screening and Visit 2, meets all necessary questionnaire scores.

Exclusion criteria

Exclusion Criteria:

Medical condition that is unstable or uncontrolled despite current therapy. History of unresolved sexual trauma or abuse. Pregnant or nursing. Lifelong anorgasmia, vaginismus, sexual pain disorder, sexual aversion disorder, or persistent sexual arousal disorder.

Female sexual dysfunction caused by untreated endocrine disease. Has or has had any of the following: , other infectious hepatitis, infectious blood disorders such as ; myocardial infarction;stroke.

Has or has had any of the following within 12 months before Screening:chronic dyspareunia not attributable to vaginal dryness; pelvic inflammatory disease; chronic or complicated UTI, or an active STD other than herpes and condyloma; cervical dysplasia, including LGSIL and HGSIL and/or ASCUS with HPV; significant cervicitis as manifested by mucopurulent discharge from the cervix.

Has had any of the following within 6 months before Screening:≥ 2 outbreaks of genital herpes; occurrence/recurrence of condyloma;clinically unstable angina or clinically unstable arrhythmia;significant CNS diseases; or ALT concentrations > 3 times the ;serum creatinine > 2.5 mg/dL;any other clinically significant abnormal laboratory result.

Has used prohibited medications within the 3 months before Screening:

Has currently active moderate to severe vaginitis or a clinically significant vaginal infection.

Has one or more significant gynecologic conditions . Is taking or has received treatment for psychosis, bipolar disorder, depression, and/or alcohol/substance abuse within 6 months before Screening.

Is currently receiving psychotherapy for the treatment of FSAD and/or HSDD. Has any of the following: Uncontrolled hypertension;Systolic BP of ≥ 140 mm Hg at Screening;Diastolic BP of ≥ 90 mm Hg at Screening; Treatment for hypertension that has changed in the 3 months before Screening.

Had a hysterectomy with bilateral oophorectomy. Had a hysterectomy without bilateral oophorectomy AND meets several other criteria.

Is taking that have affected the menstrual cycle or caused amenorrhea AND did not have a normal menstrual cycle before starting the contraceptive medication.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
612 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product.

    Drug: bremelanotide

  • Experimental
    bremelanotide arm 1

    Low dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.

    Drug: bremelanotide

  • Experimental
    bremelanotide arm 2

    Middle dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 1.25 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.

    Drug: bremelanotide

  • Experimental
    bremelanotide arm 3

    High dose: Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.

    Drug: bremelanotide

Interventions

  • Subjects will administer drug on an as needed basis, prior to anticipated sexual activity. Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75, 1.25, or 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen. Placebo: Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product.

    Also known as: PT-141

06

What researchers measure

Primary outcomes

  1. The Primary Efficacy Endpoint is Change From Baseline to End of Study in the Number of Satisfying Sexual Events (SSE)

    The primary efficacy endpoint is change from baseline to end of study in the number of satisfying sexual events (SSEs), computed as the number of events during the last 4 weeks of treatment with FSEP-R Q10 = "Yes" minus the number of baseline events with FSEP-R Q10 = "Yes." Efficacy analyses were done with the MITT population which consisted of all randomized subjects who took at least 1 dose of double-blind treatment after the 2 in-clinic doses of double-blind medication and who had at least 1 follow-up visit (Visit 10 or later) to ensure that FSEP-R data were reviewed and confirmed by the investigative site.

    Time frame: 4 - 12 weeks from baseline to end of study (total study duration 20 weeks). Baseline was the 4-week single-blind placebo period.

Secondary outcomes

  1. Change From Baseline to End-of-Study in Arousal Domain Score From Female Sexual Function Index

    The FSFI is brief self-report questionnaire that measures female sexual function. The change from baseline to end of study in the arousal domain were obtained from the FSFI Q3 through Q6. The score range is 0-5. For each of the 2 time points, the score was computed programmatically using the algorithm described by Rosen \[6\], resulting in a score from 0 (min) to 6 (max).

    Time frame: 4-12 weeks from baseline to end of study (total study duration 20 weeks)

  2. Satisfaction With Arousal as Measured by GAQ Question 1

    This is the change in Baseline to End-of-Study in Satisfaction with Arousal as measured by GAQ Question 1. GAQ (Global Assessment Questions) is a questionnaire that evaluates overall satisfaction level experienced while using the study drug. Question 1 is "Compared to the start of the study (prior to taking the study drug), how would you describe your satisfaction with your arousal while using the study drug?" The score range is 1 (very much worse) to 7 (very much better).

    Time frame: 4-12 weeks from baseline to end of study (total study duration 20 weeks)

  3. Desire Domain From Female Sexual Function Index

    The FSFI is brief self-report questionnaire that measures female sexual function. The change from baseline to end of study in the desire domain were obtained from the FSFI Q1 and Q2. The score range is 1-5. For each of the 2 time points, the score was computed programmatically using the algorithm described by Rosen \[6\], resulting in a score from 0 (min) to 6 (max).

    Time frame: 4-12 weeks from baseline to end of study (total study duration 20 weeks)

  4. Satisfaction With Desire as Measured by GAQ Question 2

    This is the change in Baseline to End-of-Study in Satisfaction with Desire as Measured by GAQ Question 2. GAQ (Global Assessment Questions) is a questionnaire that evaluates overall satisfaction level experienced while using the study drug. Question 2 is "Compared to the start of the study (prior to taking the study drug), how would you describe your satisfaction with your desire while using the study drug?" The score range is 1 (very much worse) to 7 (very much better).

    Time frame: 4-12 weeks from baseline to end of study (total study duration 20 weeks)

  5. Quality of Relationship With Partner as Measured by GAQ Question 4

    This is the change in Baseline to End-of-Study in Quality of Relationship with Partner as Measured by GAQ Question 4. GAQ (Global Assessment Questions) is a questionnaire that evaluates overall satisfaction level experienced while using the study drug. Question 4 is "Compared to the start of the study (prior to taking the study drug), how has taking the study drug changed your relationship with your partner?" The score range is 1 (very much worse) to 7 (very much better).

    Time frame: 4-12 weeks from baseline to end of study (total study duration 20 weeks)

  6. FSDS-DAO Total Score

    FSDS-DAO (Female Sexual Distress Scale - Desire/Arousal/Orgasm) is an assessment tool to measure female sexual distress. The change from baseline to end of study in the FSDS-DAO (total score) was measured. There are 15 questions, eg, "How often do you feel: Distressed about your sex life" and the score range was 0 (Never), 1 (Rarely), 2 (Occasionally), 3 (Frequently), 4 (Always). The score for each subject at each time point was computed as the sum of the scores from the 15 questions, resulting in a possible score at each time point between 0 and 60.

    Time frame: 4 - 12 weeks from baseline to end of study (total study duration 20 weeks)

07

Results

Posted Apr 14, 2014

Participant flow

A total of 1142 subjects were screened at 69 medical sites in the US and Canada, 612 subjects were enrolled, and 488 subjects entered the single-blind placebo treatment period; 397 were randomized, and 394 were dosed with randomized treatment.

Participant flow — Overall Study
MilestonePlaceboBremelanotide Arm 1Bremelanotide Arm 2Bremelanotide Arm 3
Started9810010099
Subjects not dosed1011
Completed80816666
Not completed18193433

Outcome measures

PrimaryThe Primary Efficacy Endpoint is Change From Baseline to End of Study in the Number of Satisfying Sexual Events (SSE)

The primary efficacy endpoint is change from baseline to end of study in the number of satisfying sexual events (SSEs), computed as the number of events during the last 4 weeks of treatment with FSEP-R Q10 = "Yes" minus the number of baseline events with FSEP-R Q10 = "Yes." Efficacy analyses were done with the MITT population which consisted of all randomized subjects who took at least 1 dose of double-blind treatment after the 2 in-clinic doses of double-blind medication and who had at least 1 follow-up visit (Visit 10 or later) to ensure that FSEP-R data were reviewed and confirmed by the investigative site.

Time frame:
4 - 12 weeks from baseline to end of study (total study duration 20 weeks). Baseline was the 4-week single-blind placebo period.
Reported as:
Mean · SSEs
The Primary Efficacy Endpoint is Change From Baseline to End of Study in the Number of Satisfying Sexual Events (SSE)
SSEsPlaceboBremelanotide Arm 1Bremelanotide Arm 2Bremelanotide Arm 3
The Primary Efficacy Endpoint is Change From Baseline to End of Study in the Number of Satisfying Sexual Events (SSE)0.2 ± 2.290.6 ± 3.550.7 ± 1.810.8 ± 2.86
Statistical analysis
  • Placebo vs Bremelanotide Arm 3 · Van Elteren · p = <0.05 · Mean difference (final values): 0.0215 · 95% CI 0.0 to 1.0
  • Placebo vs Bremelanotide Arm 1 vs Bremelanotide Arm 2 vs Bremelanotide Arm 3 · Van Elteren · p = <0.05 · Mean difference (final values): 0.0012 · 95% CI 0.00 to 0.06
SecondaryChange From Baseline to End-of-Study in Arousal Domain Score From Female Sexual Function Index

The FSFI is brief self-report questionnaire that measures female sexual function. The change from baseline to end of study in the arousal domain were obtained from the FSFI Q3 through Q6. The score range is 0-5. For each of the 2 time points, the score was computed programmatically using the algorithm described by Rosen \[6\], resulting in a score from 0 (min) to 6 (max).

Time frame:
4-12 weeks from baseline to end of study (total study duration 20 weeks)
Reported as:
Mean · units on a scale
Change From Baseline to End-of-Study in Arousal Domain Score From Female Sexual Function Index
units on a scalePlaceboBremelanotide Arm 1Bremelanotide Arm 2Bremelanotide Arm 3
Change From Baseline to End-of-Study in Arousal Domain Score From Female Sexual Function Index0.51 ± 1.3710.35 ± 1.4570.71 ± 1.1121.06 ± 1.146
Statistical analysis
  • Placebo vs Bremelanotide Arm 1 vs Bremelanotide Arm 2 vs Bremelanotide Arm 3 · ANCOVA · p = <0.05 · Mean difference (final values): 0.0496
SecondarySatisfaction With Arousal as Measured by GAQ Question 1

This is the change in Baseline to End-of-Study in Satisfaction with Arousal as measured by GAQ Question 1. GAQ (Global Assessment Questions) is a questionnaire that evaluates overall satisfaction level experienced while using the study drug. Question 1 is "Compared to the start of the study (prior to taking the study drug), how would you describe your satisfaction with your arousal while using the study drug?" The score range is 1 (very much worse) to 7 (very much better).

Time frame:
4-12 weeks from baseline to end of study (total study duration 20 weeks)
Reported as:
Mean · units on a scale
Satisfaction With Arousal as Measured by GAQ Question 1
units on a scalePlaceboBremelanotide Arm 1Bremelanotide Arm 2Bremelanotide Arm 3
Satisfaction With Arousal as Measured by GAQ Question 10.4 ± 1.370.3 ± 1.430.5 ± 1.460.9 ± 1.18
Statistical analysis
  • Placebo vs Bremelanotide Arm 3 · Van Elteren · p = <0.05 · Mean difference (final values): 0.0079 · 95% CI 0.00 to 1.00
SecondaryDesire Domain From Female Sexual Function Index

The FSFI is brief self-report questionnaire that measures female sexual function. The change from baseline to end of study in the desire domain were obtained from the FSFI Q1 and Q2. The score range is 1-5. For each of the 2 time points, the score was computed programmatically using the algorithm described by Rosen \[6\], resulting in a score from 0 (min) to 6 (max).

Time frame:
4-12 weeks from baseline to end of study (total study duration 20 weeks)
Reported as:
Mean · units on a scale
Desire Domain From Female Sexual Function Index
units on a scalePlaceboBremelanotide Arm 1Bremelanotide Arm 2Bremelanotide Arm 3
Desire Domain From Female Sexual Function Index0.39 ± 1.0750.33 ± 1.0930.55 ± 0.7940.95 ± 1.003
Statistical analysis
  • Placebo vs Bremelanotide Arm 3 · Van Elteren · p = <0.05 · Mean difference (final values): 0.0012
SecondarySatisfaction With Desire as Measured by GAQ Question 2

This is the change in Baseline to End-of-Study in Satisfaction with Desire as Measured by GAQ Question 2. GAQ (Global Assessment Questions) is a questionnaire that evaluates overall satisfaction level experienced while using the study drug. Question 2 is "Compared to the start of the study (prior to taking the study drug), how would you describe your satisfaction with your desire while using the study drug?" The score range is 1 (very much worse) to 7 (very much better).

Time frame:
4-12 weeks from baseline to end of study (total study duration 20 weeks)
Reported as:
Mean · units on a scale
Satisfaction With Desire as Measured by GAQ Question 2
units on a scalePlaceboBremelanotide Arm 1Bremelanotide Arm 2Bremelanotide Arm 3
Satisfaction With Desire as Measured by GAQ Question 20.4 ± 1.310.3 ± 1.320.8 ± 1.440.9 ± 1.20
Statistical analysis
  • Placebo vs Bremelanotide Arm 3 · Van Elteren · p = <0.05 · Mean difference (final values): 0.0013
SecondaryQuality of Relationship With Partner as Measured by GAQ Question 4

This is the change in Baseline to End-of-Study in Quality of Relationship with Partner as Measured by GAQ Question 4. GAQ (Global Assessment Questions) is a questionnaire that evaluates overall satisfaction level experienced while using the study drug. Question 4 is "Compared to the start of the study (prior to taking the study drug), how has taking the study drug changed your relationship with your partner?" The score range is 1 (very much worse) to 7 (very much better).

Time frame:
4-12 weeks from baseline to end of study (total study duration 20 weeks)
Reported as:
Mean · units on a scale
Quality of Relationship With Partner as Measured by GAQ Question 4
units on a scalePlaceboBremelanotide Arm 1Bremelanotide Arm 2Bremelanotide Arm 3
Quality of Relationship With Partner as Measured by GAQ Question 40.3 ± 1.200.3 ± 1.240.4 ± 1.220.6 ± 1.22
Statistical analysis
  • Placebo vs Bremelanotide Arm 3 · Van Elteren · p = <0.05 · Mean difference (final values): 0.1161
SecondaryFSDS-DAO Total Score

FSDS-DAO (Female Sexual Distress Scale - Desire/Arousal/Orgasm) is an assessment tool to measure female sexual distress. The change from baseline to end of study in the FSDS-DAO (total score) was measured. There are 15 questions, eg, "How often do you feel: Distressed about your sex life" and the score range was 0 (Never), 1 (Rarely), 2 (Occasionally), 3 (Frequently), 4 (Always). The score for each subject at each time point was computed as the sum of the scores from the 15 questions, resulting in a possible score at each time point between 0 and 60.

Time frame:
4 - 12 weeks from baseline to end of study (total study duration 20 weeks)
Reported as:
Mean · units on a scale
FSDS-DAO Total Score
units on a scalePlaceboBremelanotide Arm 1Bremelanotide Arm 2Bremelanotide Arm 3
FSDS-DAO Total Score-6.8 ± 13.57-7.4 ± 13.47-9.2 ± 10.79-13.1 ± 12.93
Statistical analysis
  • Placebo vs Bremelanotide Arm 3 · ANCOVA · p = <0.05 · Mean difference (final values): 0.0133

Adverse events

Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—3/97 (3.1%)49/97 (50.5%)
Bremelanotide Arm 1—1/100 (1%)64/100 (64%)
Bremelanotide Arm 2—1/99 (1%)61/99 (61.6%)
Bremelanotide Arm 3—1/98 (1%)67/98 (68.4%)
Most frequent serious events
Most frequent serious events
EventPlaceboBremelanotide Arm 1Bremelanotide Arm 2Bremelanotide Arm 3
Escherichia bacteremiaInfections and infestations1/970/1000/990/98
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/970/1000/990/98
MenometrorrhagiaReproductive system and breast disorders1/970/1000/990/98
Chest painCardiac disorders0/970/1000/991/98
Incisional herniaSurgical and medical procedures0/970/1001/990/98
AsthmaRespiratory, thoracic and mediastinal disorders0/971/1000/990/98
Most frequent other events
Showing 10 of 37
Most frequent other events
EventPlaceboBremelanotide Arm 1Bremelanotide Arm 2Bremelanotide Arm 3
NauseaGastrointestinal disorders3/9718/10022/9924/98
FlushingVascular disorders0/9717/10015/9917/98
HeadacheNervous system disorders3/979/10010/9915/98
Vag hemorrh/discharge, breast tend/mass, metrorrhagia, menstru irreg, genit discomfort/order (1% ea)Reproductive system and breast disorders7/973/1004/999/98
Upper respiratory tract infectionInfections and infestations4/979/1005/994/98
Injection/vessel puncture site hematoma (1% each)General disorders1/975/1008/994/98
Urinary tract infectionInfections and infestations1/977/1008/990/98
CPK/glu/lipase/chol/BP/triglycerides increased, iron decreased, MCV abnormal (1% each)Investigations3/978/1004/995/98
Fungal infect, gastroenter/bronchitis, vulvo/vaginitis, follicul/pharyngitis, tooth abcess (1% each)Infections and infestations7/977/1004/997/98
Injection site painGeneral disorders3/976/1006/997/98

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboBremelanotide Arm 1Bremelanotide Arm 2Bremelanotide Arm 3Total
Mean37.0 ± 7.7037.6 ± 7.7635.7 ± 7.2237.0 ± 7.5636.9 ± 7.57
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboBremelanotide Arm 1Bremelanotide Arm 2Bremelanotide Arm 3Total
Female971009998394
Male00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboBremelanotide Arm 1Bremelanotide Arm 2Bremelanotide Arm 3Total
American Indian or Alaska Native21115
Asian00022
Native Hawaiian or Other Pacific Islander10001
Black or African American1925322399
White75716570281
Other03025
Unknown or Not Reported00101
Weight
Weight(Pound)PlaceboBremelanotide Arm 1Bremelanotide Arm 2Bremelanotide Arm 3Total
Mean164.40 ± 42.050168.17 ± 37.867173.97 ± 43.229179.15 ± 45.872171.41 ± 42.532
Body Mass Index
Body Mass Index(kg/m2)PlaceboBremelanotide Arm 1Bremelanotide Arm 2Bremelanotide Arm 3Total
Mean27.73 ± 6.17128.47 ± 6.61629.17 ± 7.09629.92 ± 7.18128.82 ± 6.802
Of Childbearing Potential
Of Childbearing Potential(Participants)PlaceboBremelanotide Arm 1Bremelanotide Arm 2Bremelanotide Arm 3Total
Of Childbearing Potential72767065283
Surgically Sterile25242932110
Data Missing00011
Weight Quartile
Weight Quartile(Pound)PlaceboBremelanotide Arm 1Bremelanotide Arm 2Bremelanotide Arm 3Total
95 - 143 pounds37212321102
>143 - 165 pounds18362524103
>165 - 200.6 pounds23262824101
>200.6 - 350 pounds1917232887
Data Missing00011
Menses Frequency
Menses Frequency(Participants)PlaceboBremelanotide Arm 1Bremelanotide Arm 2Bremelanotide Arm 3Total
Variable cycle length (<7 days different from nor344415
Regular72758679312
Variable cycle length (>7 days different from nor721212
2 or more skipped cycles, and amenorrhea for 60 or262111
N.A.131361244

3 further baseline measures are reported on the registry.

08

Study locations

68 sites
  • Site 56
    Birmingham, Alabama 35209, United States
  • Site 26
    Huntsville, Alabama 35801, United States
  • Site 64
    Mobile, Alabama 36608, United States
  • Site 45
    Chandler, Arizona 85224, United States
  • Site 39
    Phoenix, Arizona 85032, United States
  • Site 25
    Tucson, Arizona 85712, United States
  • Site 78
    Hot Springs, Arkansas 71901, United States
  • Site 16
    Jonesboro, Arkansas 72401, United States
  • Site 52
    National City, California 91950, United States
  • Site 73
    Newport Beach, California 92880, United States
  • Site 80
    Sacramento, California 95821, United States
  • Site 12
    San Diego, California 92120, United States
  • Site 37
    Denver, Colorado 80218, United States
  • Site 40
    Lakewood, Colorado 80228, United States
  • Site 8
    Avon, Connecticut 06117, United States
  • Site 75
    Farmington, Connecticut 06032, United States
  • Site 33
    New London, Connecticut 06320, United States
  • Site 32
    Washington, District of Columbia 20036, United States
  • Site 10
    Aventura, Florida 33180, United States
  • Site 27
    Fort Myers, Florida 33916, United States
  • Site 66
    Melbourne, Florida 32935, United States
  • Site 61
    Orlando, Florida 32806, United States
  • Site 1
    West Palm Beach, Florida 33401, United States
  • Site 82
    Atlanta, Georgia 30328, United States
  • Site 55
    Decatur, Georgia 30030, United States
  • Site 70
    Chicago, Illinois 60654, United States
  • Site 54
    Peoria, Illinois 61602, United States
  • Site 63
    South Bend, Indiana 46545, United States
  • Site 13
    Wichita, Kansas 67226, United States
  • Site 48
    Lexington, Kentucky 40509, United States
  • Site 57
    Zachary, Louisiana 70791, United States
  • Site 9
    Baltimore, Maryland 21093, United States
  • Site 60
    Rockville, Maryland 20850, United States
  • Site 74
    St. Louis, Missouri 63141, United States
  • Site 35
    Lincoln, Nebraska 68510, United States
  • Site 72
    Las Vegas, Nevada 89113, United States
  • Site 24
    Las Vegas, Nevada 89128, United States
  • Site 18
    New York, New York 10016, United States
  • Site 38
    Purchase, New York 10577, United States
  • Site 3
    Raleigh, North Carolina 27612, United States
  • Site 47
    Winston-Salem, North Carolina 27103, United States
  • Site 23
    Beachwood, Ohio 44122, United States
  • Site 69
    Canton, Ohio 44718, United States
  • Site 71
    Cincinnati, Ohio 45249, United States
  • Site 19
    Cleveland, Ohio 44124, United States
  • Site 30
    Columbus, Ohio 43213, United States
  • Site 81
    Englewood, Ohio 45322, United States
  • Site 2
    Eugene, Oregon 97401, United States
  • Site 42
    Philadelphia, Pennsylvania 19107, United States
  • Site 77
    Pittsburgh, Pennsylvania 15206, United States
  • Site 43
    Warwick, Rhode Island 02886, United States
  • Site 58
    Greer, South Carolina 29650, United States
  • Site 49
    Mt. Pleasant, South Carolina 29464, United States
  • Site 53
    Chattanooga, Tennessee 37404, United States
  • Site 59
    Corpus Christi, Texas 78414, United States
  • Site 76
    Dallas, Texas 75231, United States
  • Site 31
    Dallas, Texas 75234, United States
  • Site 17
    Houston, Texas 77054, United States
  • Site 62
    San Antonio, Texas 78229, United States
  • Site 50
    Murray, Utah 84123, United States
  • Site 36
    Sandy, Utah 84070, United States
  • Site 7
    Charlottesville, Virginia 22903, United States
  • Site 68
    Norfolk, Virginia 23502, United States
  • Site 65
    Richmond, Virginia 23294, United States
  • Site 22
    Seattle, Washington 98105, United States
  • Site 4
    North Vancouver, British Columbia V7N 2H5, Canada
  • Site 41
    Barrie, Ontario L4M 7G1, Canada
  • Site 21
    Burlington, Ontario L7R4G1, Canada
09

References and documents

Publications

  • Derogatis LR, Revicki DA, Rosen RC, Jordan R, Lucas J, Spana C. Psychometric validation of the Female Sexual Distress Scale-Desire/Arousal/Orgasm. J Patient Rep Outcomes. 2021 Sep 24;5(1):100. doi: 10.1186/s41687-021-00359-1. PubMed 34559353 ↗
  • Clayton AH, Althof SE, Kingsberg S, DeRogatis LR, Kroll R, Goldstein I, Kaminetsky J, Spana C, Lucas J, Jordan R, Portman DJ. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond). 2016 Jun;12(3):325-37. doi: 10.2217/whe-2016-0018. Epub 2016 May 16. PubMed 27181790 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2011, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2011
First posted
Jun 27, 2011
Start
Jun 2011
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Results first posted
Apr 14, 2014
Last update
Dec 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01382719
Lead sponsor
Palatin Technologies, Inc
Responsible party
Sponsor
First posted
Jun 27, 2011
Start date
Jun 2011
Primary completion
Sep 2012
Completion
Sep 2012
Results posted
Apr 14, 2014
Last update
Dec 18, 2014

Study contacts

Jeffrey Edelson, MD, FRCPC
study director · Palatin Technologies, Inc

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bremelanotide

Start the discussion